A federal court has dismissed a case brought by the World Professional Association for Transgender Health (WPATH) against the Federal Trade Commission (FTC), declaring the matter moot. The ruling came after the FTC withdrew a Civil Investigative Demand (CID) that WPATH claimed violated its First Amendment rights. This decision affects WPATH and its ongoing efforts to advocate for gender-affirming medical care, as it navigates the legal landscape surrounding its practices.

The case, formally known as Civil Action No. 2026-0532, was presided over by Chief Judge James E. Boasberg in the District Court for the District of Columbia. The court's ruling emphasizes the importance of the CID's withdrawal, stating that without it, there is no longer a live controversy for the court to address.

Background

WPATH is a nonprofit organization dedicated to ensuring access to medically necessary healthcare for transgender individuals. It publishes clinical guidelines known as Standards of Care to support healthcare providers in delivering appropriate care to transgender patients. The organization has been instrumental in advocating for gender-affirming treatments, which align patients' physical appearances with their gender identities.

The dispute began when the FTC, under the Trump administration, issued a CID to WPATH in January 2026. The CID sought extensive information about WPATH's advocacy and medical practices regarding gender-affirming care. WPATH responded by filing a lawsuit against the FTC, claiming that the CID infringed upon its First Amendment rights, including free speech and association. WPATH argued that the CID was retaliatory and aimed at suppressing its advocacy efforts.

Following the lawsuit, the court granted a preliminary injunction, indicating that WPATH was likely to succeed in proving that the CID was issued in retaliation for its protected speech. However, the FTC continued its investigation through other means, ultimately leading to a civil enforcement action against WPATH in the Northern District of Texas. On the same day as the enforcement action, the FTC formally withdrew the CID, stating that it was no longer necessary.

The Ruling

The court ruled that WPATH's case against the FTC was moot due to the withdrawal of the CID. Chief Judge Boasberg noted, "With no CID pending or certainly impending, there is nothing for this Court to enjoin." The court emphasized that since the CID had been withdrawn, it could not provide any effective relief to WPATH regarding its claims.

Judge Boasberg acknowledged that there was likely evidence supporting WPATH's assertion that the FTC had violated its First Amendment rights through the issuance of the CID. However, he concluded that because the CID no longer existed, the court could not grant any further relief. He stated, "This Court does not have jurisdiction to castigate federal agencies for past irresponsible or even unlawful conduct when its decree can have no concrete effect on the parties’ present rights and obligations."

Impact

This ruling has significant implications for WPATH and similar organizations advocating for transgender healthcare. By dismissing the case as moot, the court has effectively limited WPATH's ability to challenge the FTC's actions related to the CID. The ruling sets a precedent that could affect how federal agencies engage with organizations advocating for gender-affirming care in the future.

WPATH's claims were primarily focused on the CID, and the court found that the organization could not assert broader claims against the FTC's investigation. This limitation may hinder WPATH's ability to protect its rights and advocate for transgender healthcare without the threat of similar investigations in the future.

What's Next

While WPATH's case against the FTC has been dismissed, the organization may still face challenges from the ongoing enforcement action in Texas. WPATH has indicated its intention to continue advocating for transgender healthcare despite the legal hurdles. It remains to be seen whether WPATH will pursue further legal action in response to the FTC's enforcement efforts in Texas or seek to challenge the broader implications of the FTC's investigation.